KUREBAYASHI Yoichi
D.V.M., Ph.D.
After engaging in drug discovery research at pharmaceutical companies, I have been involved in advancing basic and applied research in the life sciences at universities and national research institutes. I am committed to leveraging my knowledge and experience gained across academia, industry, and government to translate the cutting-edge science of RIKEN into innovative therapeutics and medical technologies.
FUJII Shin-ichiro
M.D., Ph.D.
After gaining clinical experience as a hematologist, including hematopoietic stem cell transplantation, I have been studying immunology with the aim of discovering drugs that control immunity. To translate scientific evidence obtained from basic research into drug discovery, it is necessary to conduct preclinical studies not only on drug efficacy but also on safety and pharmacokinetics and to evaluate the results from a clinical perspective. We will provide support for the translation of basic research into clinical practice.
KOIZUMI Tomonobu
Ph.D.
Using the cross-appointment system, I led and promoted drug discovery research from the dual standpoints of a pharmaceutical company and a university. In addition, I served as an advisor in AMED/JST projects. By leveraging these industry–academia–government collaborations for drug discovery, I will contribute to the social implementation of excellent academic outcomes.
HONMA Teruki
Ph.D.
I have been involved in drug design in 14 years at pharma and 15 years at RIKEN. Recently, I was assigned as the principal investigator in AMED Next-Generation Drug Discovery AI Project (DAIIA). We aim to develop design methods that integrate molecular simulations and AI, in particular, FMODB, the world's first quantum chemical calculation database for proteins, were released.
OZAKI Ken-ichi Ph.D.
I led drug discovery research in the research division of a pharmaceutical company and worked in their business division to promote personalized healthcare and maximize the value of development projects based on competitive intelligence. With a belief in “Right Target - Right Drug - Right Patient,” I am driven to contribute to the integration of scientific innovation into society.
SUGIBAYASHI Tomoe
I performed biopharmaceutical quality research and led business evaluations to guide decisions on in- and out-licensing and to promote product development. I am committed to drawing on my previous corporate experience to bring innovative and valuable medicines from academia to patients worldwide.
CHIBA Nobuyoshi Ph.D.
Building on my experience in research and development at resource and pharmaceutical companies, as well as my work at NEDO and AMED supporting the translation of academic research into practice, I aim to apply my knowledge and expertise to bridge RIKEN’s cutting-edge research with the development of innovative therapeutics and medical technologies.
YAMAUCHI Rikako
Ph.D.
Drawing on my diverse experience in drug discovery pharmacology research, project management, product strategy planning, academic collaborations and new business development in a pharmaceutical company, together with my bio-venture experience, I will contribute to the creation of new treatments that will bring relief and smiles to patients and their families, and that Japan can be proud of by developing innovative seeds and technologies from within and outside RIKEN.
The Strategic Alliance Office handles alliances for collaboration with companies, universities, and external research institutes. It is also involved in licensing intellectual property rights to companies in collaboration with RIKEN Innovation.
Mission of Translational Research Office (TRO), the competent team which consists of number of experts of translational research (TR) from industry, academic TR institutes, regulatory organizations, is to support projects establishing clinical development plan.
